About the company

Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. They serve customers from pharma, biotech, agriculture, and cosmetics offering peptides and proteins at highest qualities, within weeks, in a sustainable way. In this context partnership deals with global CDMO PolyPeptide and the world’s leading animal health company Zoetis were closed.
Founded in 2017 as a spin-out of Düsseldorf University, Numaferm has grown to over 20 staff.

Do you want to

know more about this company?

Zum Artikel

Dr. Anke Caßing Principal

Dr. Anke CaßingPrincipal

NUMAFERM in the news

Zum Artikel

Press

18. September 2017

Evonik is investing in NUMAFERM, a specialist in the biotechnological production of peptides

Zum Artikel

Press

11. May 2017

NUMAFERM revolutionizes peptide production and receives seed financing

More startups from Life Sciences